Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).

abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

journal_title：Cancer chemotherapy and pharmacology

authors： Katori H,Tsukuda M,Watai K

更新日期：2007-08-01 00:00:00

abstract：:Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation. First, eligible patients were divided into two groups (solitary and multiple) and then t...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsushima T,Matsumura Y,Ozaki Y,Yoshimoto J,Ohmori H

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Studies were conducted on oryzalin (3,5-dinitro-N,N-di(n-propyl)sulfanilamide), a widely used dinitroaniline sulfonamide herbicide, which was identified from plant extracts as an inhibitor of mitogen- and growth factor-mediated intracellular free Ca2+ ([Ca2+]i) signalling in mammalian cells. METHODS AND RESULT...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Gallegos A,Abraham RT,Ashendel CL,Zalkow LH,Dorr R,Dvorakova K,Salmon S,Harrison S,Worzalla J

更新日期：1997-01-01 00:00:00

abstract：:Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastr...

journal_title：Cancer chemotherapy and pharmacology

authors： Joel SP,Clark PI,Slevin ML

更新日期：1995-01-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang J,Zhang L,Wang Y,Zhao G

更新日期：2016-05-01 00:00:00

abstract：PURPOSE:Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors. ME...

journal_title：Cancer chemotherapy and pharmacology

authors： Nemunaitis J,Young A,Ejadi S,Miller W,Chen LC,Nichols G,Blotner S,Vazvaei F,Zhi J,Razak A

更新日期：2018-03-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs. METHODS:The antitumor activity of fourteen anticancer drugs was tested in over one hundred tumor samples from pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Haglund C,Aleskog A,Nygren P,Gullbo J,Höglund M,Wickström M,Larsson R,Lindhagen E

更新日期：2012-03-01 00:00:00

abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

更新日期：2015-11-01 00:00:00

abstract：:The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

更新日期：1985-01-01 00:00:00

abstract：:Hypocrellin compounds were selected as potential photosensitizers for photodynamic therapy (PDT) owing to their high quantum yields of singlet oxygen (1O2), and facility for site-directed chemical modification to enhance phototoxicity, pharmacokinetics, solubility, and light absorption in the red spectral region, amon...

journal_title：Cancer chemotherapy and pharmacology

authors： Estey EP,Brown K,Diwu Z,Liu J,Lown JW,Miller GG,Moore RB,Tulip J,McPhee MS

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Epigenetic agents are among the newly targeted therapeutic strategies being studied with intense interest for patients with multiple myeloma. Here, we demonstrate the antitumor activity of a phenylbutyrate-based histone deacetylase (HDAC) inhibitor, (S)-HDAC42, and identify its possible targets in myeloma cells...

journal_title：Cancer chemotherapy and pharmacology

authors： Bai LY,Omar HA,Chiu CF,Chi ZP,Hu JL,Weng JR

更新日期：2011-08-01 00:00:00

abstract：:Previous studies have demonstrated that treatment with fludarabine 4 h prior to arabinosylcytosine (ara-C) potentiates the accumulation of the active triphosphate of ara-C (ara-CTP) in leukemic lymphocytes. The clinical efficacy of this combination was evaluated in 15 patients with chronic lymphocytic leukemia (CLL) t...

journal_title：Cancer chemotherapy and pharmacology

authors： Gandhi V,Robertson LE,Keating MJ,Plunkett W

更新日期：1994-01-01 00:00:00

abstract：:The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mil...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen JB,Groth S,Hansen SW,Nissen MH,Rørth M,Hansen HH

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer. METHODS:A prospective, open-label, non-randomized, phase II study was performed on 49 patients with locally advanced rectal cancer. Preoperative radiotherapy was c...

journal_title：Cancer chemotherapy and pharmacology

authors： Stojanovic S,Popov I,Radosevic-Jelic L,Micev M,Borojevic N,Nikolic V,Krivokapic Z,Kecmanovic D,Gavrilovic D,Kezic I

更新日期：2011-09-01 00:00:00

abstract：PURPOSE:Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu SV,Groshen SG,Kelly K,Reckamp KL,Belani C,Synold TW,Goldkorn A,Gitlitz BJ,Cristea MC,Gong IY,Semrad TJ,Xu Y,Xu T,Koczywas M,Gandara DR,Newman EM

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Hemolytic anemia has been noted during treatment with a variety of chemotherapeutic agents. We observed mild compensated hemolytic anemia in a patient receiving capecitabine during a randomized, controlled trial of adjuvant therapy. In order to investigate the hypothesis that hemolysis is the underlying caus...

journal_title：Cancer chemotherapy and pharmacology

authors： Nikolic-Tomasevic Z,Jelic S,Cassidy J,Filipovic-Ljeskovic I,Tomasevic Z

更新日期：2005-12-01 00:00:00

abstract：PURPOSE:Streptozocin (STZ) is a key agent for treating advanced pancreatic neuroendocrine tumors (pNET). Most STZ regimens for pNET are daily and also include 5-fluorouracil (5FU), whereas STZ monotherapy and weekly regimens have also been applied in daily practice in Japan. The present study aimed to evaluate response...

journal_title：Cancer chemotherapy and pharmacology

authors： Shibuya H,Hijioka S,Sakamoto Y,Ito T,Ueda K,Komoto I,Kobayashi N,Kudo A,Yasuda H,Miyake H,Arita J,Kiritani S,Ikeda M,Imaoka H,Ueno M,Kobayashi S,Furuta M,Nagashio Y,Murohisa G,Aoki T,Matsumoto S,Motoya M,Azemo

更新日期：2018-10-01 00:00:00

abstract：PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

更新日期：2007-03-01 00:00:00

abstract：BACKGROUND:TAP chemotherapy (paclitaxel, doxorubicin, and cisplatin) is effective for advanced and recurrent endometrial carcinoma, but has occasional severe toxicity. TEC chemotherapy (paclitaxel, epirubicin, and carboplatin) has been suggested to have less toxicity; however, the optimal dosage has yet to be determine...

journal_title：Cancer chemotherapy and pharmacology

authors： Egawa-Takata T,Ueda Y,Kuragaki C,Miyake T,Miyatake T,Fujita M,Yoshino K,Nakashima R,Okazawa M,Tsutsui T,Morishige K,Kimura T,Yamasaki M,Nishizaki T,Nagamatsu M,Ito K,Asada M,Ogita K,Wakimoto A,Yamamoto T,Nishio Y

更新日期：2011-12-01 00:00:00

abstract：:Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

journal_title：Cancer chemotherapy and pharmacology

authors： Hopkins JJ,Sawyer MB

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:Capecitabine plus cisplatin (XP) is a standard therapy for metastatic gastric cancer (mGC). However, while results from previous phase III trials suggested that the cisplatin dosage should be reduced in Japanese patients, no clinical data exist to support this. Here, we conducted a multicenter study to evaluate...

journal_title：Cancer chemotherapy and pharmacology

authors： Satake H,Iwatsuki M,Uenosono Y,Shiraishi T,Tanioka H,Saeki H,Sugimachi K,Kitagawa D,Shimokawa M,Oki E,Emi Y,Kakeji Y,Tsuji A,Akagi Y,Natsugoe S,Baba H,Maehara Y,Kyushu Study Group of Clinical Cancer.

更新日期：2017-01-01 00:00:00

abstract：PURPOSE:There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrog...

journal_title：Cancer chemotherapy and pharmacology

authors： Nuttall ME,Pendrak I,Emery JG,Nadeau DP,Fisher PW,Nicholson TA,Zhu Y,Suva LJ,Kingsbury WD,Gowen M

更新日期：2001-05-01 00:00:00

abstract：:Male Sprague-Dawley rats were given single i.p. injections of 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU) to investigate changes in hepatic microsomal cytochrome P-450 content and metabolic activity. On day 14 after treatment (20 mg/kg), cytochrome P-450 content had decreased by approximately 25% and ethylmorphine N-d...

journal_title：Cancer chemotherapy and pharmacology

authors： Stolzenbach JC,Larson RE

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. METHODS:The study was a multicentric, open label, randomized, two-treatment, two-period, two-sequ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chachad S,Purandare S,Malhotra G,Naidu R

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:We have developed and evaluated a CNS-targeted chemotherapy regimen based on the pharmacokinetic properties of the individual drugs in the combination. PATIENTS AND METHODS:In a twin-track study, 16 patients with secondary CNS lymphoma (SCNSL) and 8 with primary CNS lymphoma (PCNSL) were treated with IDARAM wh...

journal_title：Cancer chemotherapy and pharmacology

authors： Moreton P,Morgan GJ,Gilson D,Smith GM,McVerry BA,Davies JM,Mackie MJ,Bolam S,Jalihal SS,Howard MR,Parapia LA,Williams AT,Child JA,Central and Southern Lymphoma Group.

更新日期：2004-04-01 00:00:00

abstract：:The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Krivit W,Chilcote R,Pyesmany A,Anderson J,Hammond D

更新日期：1979-01-01 00:00:00

abstract：:Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-in...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Liu L,Guo Z,Liang W,He J,Huang L,Deng Q,Tang H,Pan H,Guo M,Liu Y,He Q,He J

更新日期：2017-06-01 00:00:00

abstract：:A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

更新日期：1988-01-01 00:00:00

abstract：:Infusion of 5'-dFUrd (2.0-3.0 g/m2 over 1 h on days 1-5 every 3rd week) resulted in one partial response in 21 patients with advanced and progressing colorectal cancer. No patient had received chemotherapy before the 5'-dFUrd trial. Hematological and gastrointestinal toxicity were generally mild. In 4 patients periphe...

journal_title：Cancer chemotherapy and pharmacology

authors： Fosså SD,Dahl O,Hoel R,Heier M,Loeb M

更新日期：1985-01-01 00:00:00